View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
November 7, 2011

FDA approves Edwards transcatheter aortic heart valve

The US Food and Drug Administration (FDA) has cleared Edwards Lifesciences' Sapien transcatheter aortic heart valve, designed to treat inoperable patients with severe symptomatic aortic stenosis.

The US Food and Drug Administration (FDA) has cleared Edwards Lifesciences’ Sapien transcatheter aortic heart valve, designed to treat inoperable patients with severe symptomatic aortic stenosis.

The Sapien valve, designed for transfemoral delivery in patients with severe symptomatic native aortic valve stenosis, enables transcatheter aortic valve replacement, preventing the need for cardiopulmonary bypass.

The approval follows the randomised controlled pivotal Partner trial, which evaluated the safety and effectiveness of the Sapien transcatheter valve.

The Partner trial also showed that patients receiving the Sapien valve experienced better quality of life as compared to patients in the control group.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Get important industry news and analysis sent to your inbox
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Hospital Management